RWE(실사용증거) 솔루션 시장 : 시장 규모, 점유율, 성장률, 산업 분석, 유형별, 용도별, 지역별 고찰 및 예측(2026-2034년)

Growth Factors of real world evidence (RWE) solutions Market

The global real world evidence (RWE) solutions market is witnessing rapid growth, driven by the increasing adoption of real-world data (RWD) analytics in drug development, regulatory approvals, and healthcare decision-making. Real World Evidence refers to clinical evidence obtained from the analysis of real-world data regarding the benefits and use of medical products. These solutions are increasingly utilized by pharmaceutical and biopharmaceutical companies, healthcare payers, and providers to optimize outcomes, reduce costs, and support value-based care initiatives.

As per Fortune Business Insights, the global RWE solutions market was valued at USD 20.03 billion in 2025, projected to grow to USD 22.3 billion in 2026, and reach USD 65.42 billion by 2034, exhibiting a robust CAGR of 14.40% during the forecast period. North America led the market in 2025 with a 42.11% share, driven by high adoption among pharmaceutical companies, significant R&D spending, and advanced health record systems. The U.S. market is projected to grow significantly, reaching USD 17.79 billion by 2032, fueled by regulatory support from the FDA and extensive use in clinical trials.

Market Drivers

Increasing Usage in Drug Development and Approval: RWE solutions support the drug lifecycle by enhancing clinical trial design, patient identification, and real-time decision-making. Companies leverage these solutions for testing medications, developing vaccines, and designing digital therapeutics. For example, in May 2022, Pfizer Inc. presented RWE data for its combination therapy for metastatic breast cancer, demonstrating improved outcomes. During the COVID-19 pandemic, RWE solutions helped evaluate vaccine effectiveness, such as studies showing Pfizer and Moderna vaccines reduced infection risk by 90% two weeks after the second dose. Additionally, RWE solutions reduce drug development costs by 5-50%, encouraging wider adoption.

Rising R&D Spending and Clinical Trials: The pharmaceutical industry faces high drug development costs, averaging USD 2.60 billion per new drug, with only 12% of candidates gaining FDA approval. Growing R&D investments and an increasing number of clinical trials are driving the demand for RWE solutions. The number of registered clinical trials reached 452,604 in May 2023, highlighting the global expansion of real-world data utilization.

Shift Towards Value-Based Healthcare: Healthcare systems worldwide are transitioning from volume-based to value-based care, where decisions are driven by outcomes and efficiency. Programs like the Dubai Health Authority's digital-led value-based healthcare initiative exemplify this trend. This shift enhances the relevance of RWE solutions for payers, providers, and regulators seeking evidence to support cost-effective, high-quality care.

Market Restraints

Lack of Standardized Regulations: Despite high demand, the absence of globally harmonized regulations for RWE limits adoption. Differences in data collection, analytics, and reporting create challenges in transparency, data quality, and integration. Additionally, real-world data often lacks the standardization of randomized clinical trials (RCTs), impacting reliability. These regulatory and standardization gaps may restrict market growth to some extent.

Market Segmentation

By Type:

• Clinical Setting Data: Dominant segment, accounting for 67.48% in 2026, due to increasing EHR adoption and the growing number of clinical trials.
• Claims Data: Second-largest segment, helping payers optimize reimbursement and healthcare policies.
• Pharmacy Data, Patient-Powered Data, and Others: Expected to grow due to rising chronic disease prevalence and patient-centric initiatives.

By Application:

• Pharmaceutical and Medical Device Companies: Leading segment with 62.45% market share in 2026, driven by RWE use in drug and device development, regulatory approvals, and marketing strategies.
• Healthcare Payers: Growing adoption in insurance coverage and reimbursement decisions.
• Healthcare Providers: Using RWE to improve care delivery and clinical guidelines.

Regional Outlook

North America: Dominated the market with USD 8.44 billion in 2025, projected to reach USD 8.68 billion by 2026. Growth is driven by high RWE adoption, advanced health record systems, and supportive regulations, including FDA draft guidance issued in 2022.

Europe: Strong presence, supported by initiatives such as the DARWIN EU network and EMA investment in RWD. The UK market is projected to reach USD 1.06 billion by 2026, and Germany USD 0.99 billion by 2026.

Asia Pacific: Fastest-growing region with Japan USD 1.4 billion, China USD 2.12 billion, India USD 0.98 billion by 2026, fueled by numerous contract research organizations (CROs), ongoing clinical trials, and increasing adoption of RWE solutions.

Latin America & Middle East/Africa: Moderate growth due to partnerships and increasing interest in RWE-driven research. For instance, Clarivate's partnership with Techtrials in Brazil expanded access to RWE solutions for 80% of the Brazilian population.

Competitive Landscape

The market is consolidated, led by IQVIA Inc., IBM, Cognizant, Optum Inc., Oracle, and Syneos Health, focusing on expanding service offerings, partnerships, and global presence. Recent developments include:

• December 2023: FDA renewed collaboration with Syapse to evaluate RWD study designs.
• November 2022: FDA launched a RWE program to improve the quality and acceptability of RWE in regulatory decision-making.
• May 2022: Komodo Health demonstrated its platform accelerating real-world evidence for life sciences.

Conclusion

The global real world evidence solutions market is poised to grow from USD 20.03 billion in 2025 to USD 22.3 billion in 2026, reaching USD 65.42 billion by 2034, at a CAGR of 14.40%. Growth is primarily driven by adoption in drug development, regulatory support, increasing clinical trials, and value-based healthcare initiatives. North America dominates, while Asia Pacific offers the fastest growth potential. The market's trajectory will continue to benefit from technological innovation, strategic partnerships, and rising global demand for evidence-based healthcare solutions.

Segmentation By Type

• Clinical Setting Data
• Claims Data
• Pharmacy Data
• Patient Powered Data
• Others

By Application

• Pharmaceutical and Medical Device Companies
• Healthcare Payers
• Healthcare Providers
• Others

By Region

• North America (By Type, By Application, By Country)
  • U.S.
  • Canada
• Europe (By Type, By Application, By Country/Sub-Region)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific (By Type, By Application, By Country/Sub-Region)
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• Latin America (By Type, By Application, By Country/Sub-Region)
  • Brazil
  • Mexico
  • Argentina
  • Chile
  • Rest of Latin America
• Middle East & Africa (By Type, By Application, By Country/Sub-Region)
  • South Africa
  • Egypt
  • UAE
  • Saudi Arabia
• Rest of Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Number of Clinical Trials Conducted by Key Countries/ Regions, 2022/2024
• 4.2. Key Industry Developments, By Key Players
• 4.3. Impact of COVID-19 on the Market

5. Global Real World Evidence Solutions Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Clinical Setting Data
  • 5.1.2. Claims Data
  • 5.1.3. Pharmacy Data
  • 5.1.4. Patient Powered Data
  • 5.1.5. Others
• 5.2. Market Analysis, Insights and Forecast - By Application
  • 5.2.1. Pharmaceutical and Medical Device Companies
  • 5.2.2. Healthcare Payers
  • 5.2.3. Healthcare Providers
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By Region
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. Asia Pacific
  • 5.3.4. Latin America
  • 5.3.5. Middle East & Africa

6. North America Real World Evidence Solutions Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Clinical Setting Data
  • 6.1.2. Claims Data
  • 6.1.3. Pharmacy Data
  • 6.1.4. Patient Powered Data
  • 6.1.5. Others
• 6.2. Market Analysis, Insights and Forecast - By Application
  • 6.2.1. Pharmaceutical and Medical Device Companies
  • 6.2.2. Healthcare Payers
  • 6.2.3. Healthcare Providers
  • 6.2.4. Others
• 6.3. Market Analysis, Insights and Forecast - By Country
  • 6.3.1. U.S.
  • 6.3.2. Canada

7. Europe Real World Evidence Solutions Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Clinical Setting Data
  • 7.1.2. Claims Data
  • 7.1.3. Pharmacy Data
  • 7.1.4. Patient Powered Data
  • 7.1.5. Others
• 7.2. Market Analysis, Insights and Forecast - By Application
  • 7.2.1. Pharmaceutical and Medical Device Companies
  • 7.2.2. Healthcare Payers
  • 7.2.3. Healthcare Providers
  • 7.2.4. Others
• 7.3. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.3.1. U.K.
  • 7.3.2. Germany
  • 7.3.3. France
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Rest of Europe

8. Asia Pacific Real World Evidence Solutions Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Clinical Setting Data
  • 8.1.2. Claims Data
  • 8.1.3. Pharmacy Data
  • 8.1.4. Patient Powered Data
  • 8.1.5. Others
• 8.2. Market Analysis, Insights and Forecast - By Application
  • 8.2.1. Pharmaceutical and Medical Device Companies
  • 8.2.2. Healthcare Payers
  • 8.2.3. Healthcare Providers
  • 8.2.4. Others
• 8.3. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.3.1. China
  • 8.3.2. India
  • 8.3.3. Japan
  • 8.3.4. South Korea
  • 8.3.5. Australia
  • 8.3.6. Rest of Asia Pacific

9. Latin America Real World Evidence Solutions Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Clinical Setting Data
  • 9.1.2. Claims Data
  • 9.1.3. Pharmacy Data
  • 9.1.4. Patient Powered Data
  • 9.1.5. Others
• 9.2. Market Analysis, Insights and Forecast - By Application
  • 9.2.1. Pharmaceutical and Medical Device Companies
  • 9.2.2. Healthcare Payers
  • 9.2.3. Healthcare Providers
  • 9.2.4. Others
• 9.3. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.3.1. Brazil
  • 9.3.2. Mexico
  • 9.3.3. Argentina
  • 9.3.4. Chile
  • 9.3.5. Rest of South America

10. Middle East & Africa Real World Evidence Solutions Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Type
  • 10.1.1. Clinical Setting Data
  • 10.1.2. Claims Data
  • 10.1.3. Pharmacy Data
  • 10.1.4. Patient Powered Data
  • 10.1.5. Others
• 10.2. Market Analysis, Insights and Forecast - By Application
  • 10.2.1. Pharmaceutical and Medical Device Companies
  • 10.2.2. Healthcare Payers
  • 10.2.3. Healthcare Providers
  • 10.2.4. Others
• 10.3. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.3.1. South Africa
  • 10.3.2. Egypt
  • 10.3.3. UAE
  • 10.3.4. Saudi Arabia
  • 10.3.5. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2024)
• 11.2. Company Profiles
  • 11.2.1. IQVIA, Inc.
    • 11.2.1.1. Overview
    • 11.2.1.2. Product
    • 11.2.1.3. IBM
    • 11.2.1.4. SWOT Analysis
    • 11.2.1.5. Recent Developments
    • 11.2.1.6. Strategies
    • 11.2.1.7. financials (Based on Availability)
  • 11.2.2. Cognizant
    • 11.2.2.1. Overview
    • 11.2.2.2. Product
    • 11.2.2.3. IBM
    • 11.2.2.4. SWOT Analysis
    • 11.2.2.5. Recent Developments
    • 11.2.2.6. Strategies
    • 11.2.2.7. financials (Based on Availability)
  • 11.2.3. Oracle
    • 11.2.3.1. Overview
    • 11.2.3.2. Product
    • 11.2.3.3. IBM
    • 11.2.3.4. SWOT Analysis
    • 11.2.3.5. Recent Developments
    • 11.2.3.6. Strategies
    • 11.2.3.7. financials (Based on Availability)
  • 11.2.4. Syneos Health
    • 11.2.4.1. Overview
    • 11.2.4.2. Product
    • 11.2.4.3. IBM
    • 11.2.4.4. SWOT Analysis
    • 11.2.4.5. Recent Developments
    • 11.2.4.6. Strategies
    • 11.2.4.7. financials (Based on Availability)
  • 11.2.5. Clinigen Limited (Triley Bidco Limited)
    • 11.2.5.1. Overview
    • 11.2.5.2. Product
    • 11.2.5.3. IBM
    • 11.2.5.4. SWOT Analysis
    • 11.2.5.5. Recent Developments
    • 11.2.5.6. Strategies
    • 11.2.5.7. financials (Based on Availability)
  • 11.2.6. Icon plc
    • 11.2.6.1. Overview
    • 11.2.6.2. Product
    • 11.2.6.3. IBM
    • 11.2.6.4. SWOT Analysis
    • 11.2.6.5. Recent Developments
    • 11.2.6.6. Strategies
    • 11.2.6.7. financials (Based on Availability)
  • 11.2.7. Optum, Inc. (UnitedHealth Group)
    • 11.2.7.1. Overview
    • 11.2.7.2. Product
    • 11.2.7.3. IBM
    • 11.2.7.4. SWOT Analysis
    • 11.2.7.5. Recent Developments
    • 11.2.7.6. Strategies
    • 11.2.7.7. financials (Based on Availability)
  • 11.2.8. Flatiron Health (F. Hoffmann-La Roche Ltd.)
    • 11.2.8.1. Overview
    • 11.2.8.2. Product
    • 11.2.8.3. IBM
    • 11.2.8.4. SWOT Analysis
    • 11.2.8.5. Recent Developments
    • 11.2.8.6. Strategies
    • 11.2.8.7. financials (Based on Availability)
  • 11.2.9. Thermo Fisher Scientific Inc.
    • 11.2.9.1. Overview
    • 11.2.9.2. Product
    • 11.2.9.3. IBM
    • 11.2.9.4. SWOT Analysis
    • 11.2.9.5. Recent Developments
    • 11.2.9.6. Strategies
    • 11.2.9.7. financials (Based on Availability)
  • 11.2.10. Parexel International Corporation
    • 11.2.10.1. Overview
    • 11.2.10.2. Product
    • 11.2.10.3. IBM
    • 11.2.10.4. SWOT Analysis
    • 11.2.10.5. Recent Developments
    • 11.2.10.6. Strategies
    • 11.2.10.7. financials (Based on Availability)
  • 11.2.11. SAS Institute, Inc.
    • 11.2.11.1. Overview
    • 11.2.11.2. Product
    • 11.2.11.3. IBM
    • 11.2.11.4. SWOT Analysis
    • 11.2.11.5. Recent Developments
    • 11.2.11.6. Strategies
    • 11.2.11.7. financials (Based on Availability)
  • 11.2.12. PerkinElmer, Inc.
    • 11.2.12.1. Overview
    • 11.2.12.2. Product
    • 11.2.12.3. IBM
    • 11.2.12.4. SWOT Analysis
    • 11.2.12.5. Recent Developments
    • 11.2.12.6. Strategies
    • 11.2.12.7. financials (Based on Availability)
  • 11.2.13. Cegedim Health Data
    • 11.2.13.1. Overview
    • 11.2.13.2. Product
    • 11.2.13.3. IBM
    • 11.2.13.4. SWOT Analysis
    • 11.2.13.5. Recent Developments
    • 11.2.13.6. Strategies
    • 11.2.13.7. financials (Based on Availability)